913344-40-8

Upstream product

• 31954-27-5 N-(tert-butoxycarbonyl)glycine methyl ester 
• 137618-48-5 tert-butyl N-(2,3-dihydroxypropyl)carbamate 

Downstream Products

• 1099752-19-8 tert-butyl formyl{(1S)-1-[(trityloxy)methyl]prop-2-enyl}carbamate 
• 1099752-21-2 tert-butyl formyl[(2E)-4-(trityloxy)but-2-enyl]carbamate 
• 1099752-65-4 tert-butyl formyl[(2E)-5-(trityloxy)-pent-2-enyl]carbamate 
• 91103-37-6 tert-butyl [(1S)-1-(hydroxymethyl)prop-2-en-1-yl]carbamate 
• 89985-86-4 (R)-2-(N-tert-butoxycarbonylamino)-3-buten-1-ol 
• 1198807-30-5 C₂₈H₃₁NO₃ 
• 115378-33-1 (-)-tert-butyl [(1S)-1-methylprop-2-en-1-yl]carbamate 
• 1315127-93-5 1,1-dimethylethyl ((2E)-4-{[(1,1-dimethylethyl)(diphenyl)silyl]oxy}but-2-en-1-yl)formylcarbamate 
• 1315127-91-3 (-)-1,1-dimethylethyl [(1R)-1-({[(1,1-dimethylethyl)(diphenyl)silyl]oxy}methyl)prop-2-en-1-yl]formylcarbamate 
• 158851-29-7 (+)-tert-butyl [(1R)-1-phenylprop-2-en-1-yl]imidocarbonate 
• 300363-41-1 (+)-1,1-dimethylethyl [(1R)-1-({[(1,1-dimethylethyl)(diphenyl)silyl]oxy}methyl)prop-2-en-1-yl]carbamate 
• 1315128-91-6 (-)-tert-butyl (2R,5R)-2-(2-ethoxy-2-oxoethyl)-5-phenylpyrrolidine-1-carboxylate 
• 1315128-48-3 (+)-ethyl (2Z,6R)-6-[(tert-butoxycarbonyl)amino]-6-phenylhex-2-enoate 
• 1315128-46-1 (+)-methyl (2Z,6R)-6-[(tert-butoxycarbonyl)amino]-6-phenylhex-2-enoate 

Relevant academic research and scientific papers

Tumor-Cell-Specific Targeting of Ibrutinib: Introducing Electrostatic Antibody-Inhibitor Conjugates (AiCs)

Ibrutinib is an inhibitor of Bruton's tyrosine kinase that has been approved for the treatment of patients with chronic lymphocytic leukemia, mantle cell lymphoma and Waldenstrom's macroglobulinemia and is connected with toxicities. To minimize its toxicities, we linked ibrutinib to a cell-targeted, internalizing antibody. To this end, we synthesized a poly-anionic derivate, ibrutinib-Cy3.5, that retains full functionality. This anionic inhibitor is complexed by our anti-CD20-protamine targeting conjugate and free protamine, and thereby spontaneously assembles into an electrostatically stabilized vesicular nanocarrier. The complexation led to an accumulation of the drug driven by the CD20 antigen internalization to the intended cells and an amplification of its pharmacological effectivity. In vivo, we observed a significant enrichment of the drug in xenograft lymphoma tumors in immune-compromised mice and a significantly better response to lower doses compared to the original drug.

Oxidation of α-amino acids promoted by the phthalimide N-oxyl radical: A kinetic and product study

A kinetic study of the hydrogen atom transfer (HAT) reaction from a series of N-Boc- or N-Acetyl-protected amino acids to the phthalimide N-oxyl radical (PINO) was carried out to obtain information about reactivity and selectivity patterns. With amino acids containing aliphatic side chains, the 2nd order rate constants are of the same order of magnitude, in agreement with a HAT process involving the Cα?H bond. Proline is the most reactive substrate suggesting that HAT process involves the Cδ?H bond instead of Cα?H bond. These results are confirmed by the product analysis of the aerobic oxidations of the corresponding N-Boc and N-Ac protected amino acids methyl esters promoted by N-hydroxyphthalimide. Comparison of our results with those reported for HAT reactions to other radical species indicates that PINO displays electrophilic characteristics that are intermediate between those observed for the more stable Br[rad] radical and the more reactive cumyloxyl radical.